Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,276,052
  • Shares Outstanding, K 129,812
  • Annual Sales, $ 727,330 K
  • Annual Income, $ -108,030 K
  • EBIT $ -116 M
  • EBITDA $ -46 M
  • 60-Month Beta 1.58
  • Price/Sales 1.82
  • Price/Cash Flow 30.35
  • Price/Book 1.57

Options Overview Details

View History
  • Implied Volatility 134.59% (+44.30%)
  • Historical Volatility 45.16%
  • IV Percentile 95%
  • IV Rank 54.46%
  • IV High 212.48% on 02/18/26
  • IV Low 41.44% on 08/15/25
  • Expected Move (DTE 20) 0.81 (8.21%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 205
  • Volume Avg (30-Day) 232
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 9,396
  • Open Int (30-Day) 15,147
  • Expected Range 9.02 to 10.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.08
  • Number of Estimates 4
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.28 +5.93%
on 02/17/26
12.68 -22.45%
on 02/03/26
-2.64 (-21.17%)
since 01/27/26
3-Month
9.28 +5.93%
on 02/17/26
13.74 -28.46%
on 01/12/26
-2.30 (-18.96%)
since 11/26/25
52-Week
4.72 +108.26%
on 08/01/25
13.74 -28.46%
on 01/12/26
+0.01 (+0.10%)
since 02/27/25

Most Recent Stories

More News
3 Reasons to Avoid NEO and 1 Stock to Buy Instead

3 Reasons to Avoid NEO and 1 Stock to Buy Instead

NEO : 9.83 (-3.34%)
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated

NEO : 9.83 (-3.34%)
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call

5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call

NEO : 9.83 (-3.34%)
Why NeoGenomics (NEO) Shares Are Falling Today

Why NeoGenomics (NEO) Shares Are Falling Today

NEO : 9.83 (-3.34%)
NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:...

NEO : 9.83 (-3.34%)
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO : 9.83 (-3.34%)
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates

NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates

NEO : 9.83 (-3.34%)
NeoGenomics: Q4 Earnings Snapshot

NeoGenomics: Q4 Earnings Snapshot

NEO : 9.83 (-3.34%)
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent...

NEO : 9.83 (-3.34%)
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For

NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For

NEO : 9.83 (-3.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

3rd Resistance Point 10.41
2nd Resistance Point 10.25
1st Resistance Point 10.04
Last Price 9.83
1st Support Level 9.67
2nd Support Level 9.52
3rd Support Level 9.31

See More

52-Week High 13.74
Fibonacci 61.8% 10.29
Last Price 9.83
Fibonacci 50% 9.23
Fibonacci 38.2% 8.17
52-Week Low 4.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar